1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Physician Views: Post ADA view on key diabetes market developments

Last week’s American Diabetes Association (ADA) meeting provided further evidence that the diabetes market is likely to be the pharmaceutical industry’s most competitive disease area over the next decade.

With regards to oral therapies, positive data for Eli Lilly’s dulaglutide has spurred the view among analysts that the GLP-1 agonist market will grow substantially, while players who already market products within this class – Novo Nordisk and AstraZeneca/Bristol-Myers Squibb – will also be looking at ways to accelerate revenue growth.

Similarly, forecasts for the SGLT-2 inhibitor market appear to be steadily moving upwards, driven primarily by a strong uptake for Johnson & Johnson’s Invokana.

Previous FirstWord Physician Views polls have indicated that recent FDA concern surrounding the safety of DPP-IV inhibitor products has had a minimal impact on prescribing trends among endocrinologists – a trend that is likely to solidify in light of the FDA indicating that only long term outcome studies can demonstrate if there is a significant pancreatic safety signal.

Attention has thus shifted to outcome studies, but in the short to medium term with regard to the possibility of demonstrating cardiovascular benefit versus placebo. The first of these studies read out two weeks ago – for AstraZeneca and Bristol-Myers Squibb’s Onglyza – and demonstrated non-superiority. Whilst this was widely expected, analysts have also expressed some disappointment given that sales growth for the DPP-IV class has slowed in recent months.

In the long acting insulin market, FDA rejection of Novo Nordisk’s Tresiba in February was a clear disappointment, although Sanofi looks poised to take advantage via its efforts to extend and enhance its market-leading Lantus franchise. At the ADA meeting, Sanofi released the first Phase III data for its next-generation Lantus programme (known as Lantus U300) designed to provide greater benefit in terms of reducing hypoglycaemic events. Analysts suggest this is the first evidence to realistically demonstrate that continued growth for Lantus past its patent expiry date is feasible.

Reasons to Buy this Report

In light of recent developments, this week’s Physician Views poll will ask US-based endocrinologists:

• Whether they anticipate data from the SAVOR outcomes study will impact their prescribing habits with regard to AstraZeneca and Bristol-Myers Squibb’s Onglyza
• To what percentage of GLP-1 patients they would prescribe Eli Lilly’s dulaglutide if it was available today
• By what percentage they would expect to increase their usage of AstraZeneca and Bristol-Myers Squibb’s GLP-1 agonist Bydureon if it was administered in a more convenient pen device?
• What the current level of unmet need is for novel longer acting insulins that are able to reduce the rate of hypoglycaemia
• Where they believe they are most likely to use SGLT-2 inhibitors within the treatment paradigm

Table Of Contents

Physician Views: Post ADA view on key diabetes market developments

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Global Needle-Free Diabetes Management Market Size, Share, Development, Growth and Demand Forecast to 2025 - Industry Insights by Device Type

Global Needle-Free Diabetes Management Market Size, Share, Development, Growth and Demand Forecast to 2025 - Industry Insights by Device Type

  • $ 5100
  • Industry report
  • February 2017
  • by P&S Market Research

Market Overview Needle-free diabetes management refers to treatment, diagnosis and monitoring of diabetic patients without using needles. Needle-free diabetes management devices are used for injecting ...

Diabetes Drugs Markets in China

Diabetes Drugs Markets in China

  • $ 4000
  • Industry report
  • March 2017
  • by Asia Market Information & Development Company

China’s demand for Diabetes Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth ...

Global Diabetic Therapeutic Market 2017-2021

Global Diabetic Therapeutic Market 2017-2021

  • $ 3500
  • Industry report
  • February 2017
  • by Infiniti Research Limited

About Diabetic Therapeutic The global diabetic therapeutic market is growing at a high pace owing to the increase in the prevalence of diabetes globally. The top countries with high prevalence of diabetes ...

Download Unlimited Documents from Trusted Public Sources

Glucagon Like Peptide 1 Receptor Activator Market

  • March 2017
    3 pages
  • Glucagon Like P...  



View report >

Arthritis Statistics in Iran

  • March 2017
    4 pages
  • Arthritis  

  • Iran  

    United States  

View report >

Therapy Market - Forecast

  • March 2017
    9 pages
  • Diabetes  

  • United States  



View report >

Related Market Segments :



Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.